Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ZLAB Zai Lab Ltd
- Stocks
- Healthcare
- NASDAQ: ZLAB
Price (delayed)
$29.43
Market cap
$3.19B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.4
Enterprise value
$2.53B
Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To
Highlights
ZLAB's gross profit is up by 45% year-on-year and by 6% since the previous quarter
Zai Lab's revenue has increased by 44% YoY and by 4.8% from the previous quarter
The equity has grown by 6% YoY but it has contracted by 3.6% from the previous quarter
The quick ratio is down by 31% year-on-year and by 9% since the previous quarter
The debt has grown by 25% from the previous quarter
Key stats
What are the main financial stats of ZLAB
Market
Valuations
Earnings
Shares outstanding
108.47M
Market cap
$3.19B
Enterprise value
$2.53B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.92
Price to sales (P/S)
7.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.04
Revenue
$418.33M
Gross profit
$265.44M
Operating income
-$272.38M
Net income
-$252.07M
EBIT
-$248.74M
EBITDA
-$227.62M
Free cash flow
-$192.65M
Per share
Balance sheet
Liquidity
EPS
-$2.4
EPS diluted
-$2.4
Free cash flow per share
-$1.78
Book value per share
$7.5
Revenue per share
$3.87
TBVPS
$10.31
Total assets
$1.17B
Total liabilities
$362.58M
Debt
$192.3M
Equity
$810.75M
Working capital
$722.06M
Debt to equity
0.24
Current ratio
3.26
Quick ratio
2.95
Net debt/EBITDA
2.92
Margins
Efficiency
Dividend
EBITDA margin
-54.4%
Gross margin
63.5%
Net margin
-60.3%
Operating margin
-65.1%
Return on assets
-23.3%
Return on equity
-33.3%
Return on invested capital
-151.5%
Return on capital employed
-29.1%
Return on sales
-59.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZLAB stock price
How has the Zai Lab stock price performed over time
Intraday
1%
1 week
-5.61%
1 month
8.76%
1 year
40.08%
YTD
12.37%
QTD
-18.57%
Financial performance
How have Zai Lab's revenue and profit performed over time
Revenue
$418.33M
Gross profit
$265.44M
Operating income
-$272.38M
Net income
-$252.07M
Gross margin
63.5%
Net margin
-60.3%
The net margin has grown by 48% YoY and by 6% from the previous quarter
The company's operating margin rose by 46% YoY and by 6% QoQ
ZLAB's gross profit is up by 45% year-on-year and by 6% since the previous quarter
Zai Lab's revenue has increased by 44% YoY and by 4.8% from the previous quarter
Price vs fundamentals
How does ZLAB's price correlate with its fundamentals
Growth
What is Zai Lab's growth rate over time
Valuation
What is Zai Lab stock price valuation
P/E
N/A
P/B
3.92
P/S
7.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.04
The EPS has grown by 31% YoY and by 8% from the previous quarter
The stock's P/B is 21% below its 5-year quarterly average of 4.9 but 11% above its last 4 quarters average of 3.5
The equity has grown by 6% YoY but it has contracted by 3.6% from the previous quarter
ZLAB's price to sales (P/S) is 88% lower than its 5-year quarterly average of 62.6 but 9% higher than its last 4 quarters average of 6.9
Zai Lab's revenue has increased by 44% YoY and by 4.8% from the previous quarter
Efficiency
How efficient is Zai Lab business performance
Zai Lab's return on invested capital has surged by 55% YoY and by 8% QoQ
The ROS has grown by 49% YoY and by 7% from the previous quarter
The ROA has grown by 28% YoY and by 6% from the previous quarter
ZLAB's ROE is up by 17% YoY and by 3.8% QoQ
Dividends
What is ZLAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZLAB.
Financial health
How did Zai Lab financials performed over time
The company's total liabilities has surged by 60% YoY and by 5% QoQ
The quick ratio is down by 31% year-on-year and by 9% since the previous quarter
The debt is 76% less than the equity
Zai Lab's debt to equity has soared by 200% YoY and by 33% from the previous quarter
The debt has grown by 25% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.